Issue
Copyright (c) 2023 Ghassan Khudhair Esmael, Tarek Rebai, Khalil Gazar Chelab Al-Nailey
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The undersigned hereby assign all rights, included but not limited to copyright, for this manuscript to CMB Association upon its submission for consideration to publication on Cellular and Molecular Biology. The rights assigned include, but are not limited to, the sole and exclusive rights to license, sell, subsequently assign, derive, distribute, display and reproduce this manuscript, in whole or in part, in any format, electronic or otherwise, including those in existence at the time this agreement was signed. The authors hereby warrant that they have not granted or assigned, and shall not grant or assign, the aforementioned rights to any other person, firm, organization, or other entity. All rights are automatically restored to authors if this manuscript is not accepted for publication.Immunomodulatory effects of bone marrow-derived Mesenchymal stem cells on BALB/c mice model with induced Systemic lupus erythematosus (SLE)
Corresponding Author(s) : Ghassan Khudhair Esmael
Cellular and Molecular Biology,
Vol. 69 No. 1: Issue 1
Abstract
Systemic lupus erythematosus (SLE) is an autoimmune inflammatory disease that causes acute inflammation in most body tissues. The current study aims to determine levels of some cytokines and chemokines in BALB/c mice with SLE and treatment by using BALB/c Mesenchymal stem cells (BM-MSCs). Forty BALB/c male mice were divided into four groups equally. The first and second groups received activated lymphocyte-derived DNA (ALD DNA) for induction of SLE. The second group received BM-MSCs/IV after the appearance of SLE clinical signs. The third group received BM-MSCs only, while the fourth group (control group) received PBS. All the study groups examine levels of IL-10, IL-6, TGFβ1, VEGF, CCL-2, CCL-5/RANTES, IFNγ, and ICAM -1 by ELISA kits. The cytokines levels are determined in all the study groups. There was a significant increase in ANA and anti-dsDNA levels in the first group, while there was a decrease in the second group (treatment by BM-MSCs). There is no significant difference between the third and control groups in ANA and anti-dsDNA levels. The first group showed a significant increase in IL-6, CCL-5/RANTES, VEGF, ICAM, CCL-2, and IFNγ levels and a decrease in IL-10 and TGFβ1. The second group showed low levels of IL-6, CCL-5/RANTES, VEGF, ICAM, CCL-2/MCP-1, and IFNγ but a high level of IL-10 and TGFβ1 as compared with the control group. The third group has no significant differences from the control group in all the tested parameters. BM-MSCs have an essential therapeutic role in the functional regulation of cytokines and chemokines in mice with SLE.
Keywords
Download Citation
Endnote/Zotero/Mendeley (RIS)BibTeX
